What smart money is saying about Solitron Devices
SODI
No fund has written a full thesis on Solitron Devices in our archive, but 1 fund letter reports a position in it — most recently Cedar Creek Partners in June 2026.
Get an email when a fund writes about it
1
Reported positions
0
Bought
0
Sold
1
Letter
Position history
Every position in Solitron Devices on record in the archive was reported in Q2 2026, across 1 fund letter, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 0 | 0 | 0 |
Fund activity · 1 position
- HoldsCedar Creek PartnersJune 2026
“Update on Our Control Position By control, we mean that the fund manager is on the Board or in a position to significantly influence decision making, not that he has total control and gets what he wants. With the sale of PharmChem in 2025 there is only one such holding in the fund at present. Solitron Devices (otc: SODI) - the bid price for shares increased from $25.00 per share to $25.50 per share during the second quarter. As a reminder, the fund manager is CEO and a board member of Solitron. The fund owns 11% of Solitron’s outstanding shares and the fund manager and his immediate family own 3%.”
Solitron Devices
Read the letters behind these Solitron Devices positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger